Saltar al contenido
Merck
  • Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Talanta (2012-01-31)
Catarina L Silva, Mário Passos, José S Câmara
RESUMEN

A sensitive assay to identify volatile organic metabolites (VOMs) as biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. Therefore the aim of this study was to establish the urinary metabolomic profile of breast cancer patients and healthy individuals (control group) and to explore the VOMs as potential biomarkers in breast cancer diagnosis at early stage. Solid-phase microextraction (SPME) using CAR/PDMS sorbent combined with gas chromatography-mass spectrometry was applied to obtain metabolomic information patterns of 26 breast cancer patients and 21 healthy individuals (controls). A total of seventy-nine VOMs, belonging to distinct chemical classes, were detected and identified in control and breast cancer groups. Ketones and sulfur compounds were the chemical classes with highest contribution for both groups. Results showed that excretion values of 6 VOMs among the total of 79 detected were found to be statistically different (p<0.05). A significant increase in the peak area of (-)-4-carene, 3-heptanone, 1,2,4-trimethylbenzene, 2-methoxythiophene and phenol, in VOMs of cancer patients relatively to controls was observed. Statistically significant lower abundances of dimethyl disulfide were found in cancer patients. Bioanalytical data were submitted to multivariate statistics [principal component analysis (PCA)], in order to visualize clusters of cases and to detect the VOMs that are able to differentiate cancer patients from healthy individuals. Very good discrimination within breast cancer and control groups was achieved. Nevertheless, a deep study using a larger number of patients must be carried out to confirm the results.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Acetona, ACS reagent, ≥99.5%
Sigma-Aldrich
Ácido acético, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
Acetona, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Ácido acético, glacial, ReagentPlus®, ≥99%
Sigma-Aldrich
Acetona, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
2-Butanona, ACS reagent, ≥99.0%
Sigma-Aldrich
Ácido acético, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
4-Methyl-2-pentanone, suitable for HPLC, ≥99.5%
Sigma-Aldrich
Ácido acético solution, suitable for HPLC
Sigma-Aldrich
4-Methyl-2-pentanone, ACS reagent, ≥98.5%
Sigma-Aldrich
Fenol solution, BioReagent, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, for molecular biology
Sigma-Aldrich
Ácido octanoico, ≥99%
Sigma-Aldrich
Acetona, ACS reagent, ≥99.5%
Sigma-Aldrich
1-Octanol, suitable for HPLC, ≥99%
Sigma-Aldrich
Hexanoic acid, ≥99%
Sigma-Aldrich
1-Octanol, ReagentPlus®, 99%
Sigma-Aldrich
Decanoic acid, ≥99.5%, FCC, FG
Sigma-Aldrich
Guaiacol, oxidation indicator
Sigma-Aldrich
Hexanal, 98%
Sigma-Aldrich
Fenol solution, BioReagent, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, for molecular biology
Sigma-Aldrich
p-Cymene, 99%
Sigma-Aldrich
Fenol, ≥99%
Sigma-Aldrich
Decanoic acid, ≥98.0%
Sigma-Aldrich
2-Heptanone, 99%
Sigma-Aldrich
Ácido acético, for luminescence, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Acetona, histological grade, ≥99.5%
Sigma-Aldrich
Guaiacol, natural, ≥99%, FG
Sigma-Aldrich
Dimethyl disulfide, ≥99.0%
Sigma-Aldrich
Ácido acético, ≥99.5%, FCC, FG
Sigma-Aldrich
4-Methyl-2-pentanone, ≥99%